1[1]Levy JH, Ramsay J, Bailey JM.Pharmacokinetics and pharmacody namics of phosphodierase- Ⅲ inhibitors.J Cardiothoras Anesth 1990, 4:7- 11
2[2]Monrad ES, McKay RG, Baim DS, et al.Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone.Circulation 1984, 70:1030- 1037
3[3]Skoyles JR, Sherry KM.Pharmacology mechanisms of action and uses of selective phosphodiester ase inhibitors.Br J Anaesth, 1992, 68(3):293- 302
4[4]Anderson JL, Baim DS, Fein SA, Goldstein RA, LeJemtel TH, Likeoff MJ.Efficacy and safety of sustained(48 hour)intravenous infusions of milrinone in patients with severe congestive heart failure:a mul- ticenter study.J Am Coll Cardiol, 1987,9:711- 722
5[5]LeJemtel Th, Maskin CS, Chadwick B, Sonnenblick H.HemodEyna- mic effects of intravenouse and oral milrinone in patients with chr- onic heart failure.In Ref,2:133- 142
6[6]Jaski BE, Fifer MA, Wright RF, et al.Positive inotropic and vasodila- tor actions of milrinone in patients with severe congestive heartfailu- re:dose- response relationship and comparison to nitroprusside.J Clin Invest, 1985,75:643- 649
7[7]Bailey JM, Levy JH, Kikura M, et al.Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery.Anesthesiology, 1994,81:616- 622
8[8]Akkerm SR, Zhang H, Mullins RE, et al.Stability of milrinone lactate in the presence of 29 critical care drugs and 4 i.v. soluchrns.Am J Health Syst Pharm,1999,56:63- 68
9[9]Braunwald E.Heart failure :evaluation of therapy based on a con sideration of natural history.In:Braunwald E, Sonnenblick EH, Chakrin LW, Schwarz RP Jr, eds.Milrinone:Investigation of New Inotropic Therapy for Congestive Heart Failure.New York:Raven, 1984:1- 13
10[10]Feldman AM, Bristow MR.The β - adrenergic pathway in the failing heart:Implications for inotropic therapy.Cardiology, 1990,77(Suppl 1):1- 32
